Depression Case
Testimonials
Obesity, OCD, and Depression
Case study
Rebecca Provorse ND
Portland, Oregon
Depression
Case Testimonials:
36yo female presents
with complaint of premenstrual disphoric disorder
(PMDD), onset with menarche at age 13 and becoming
severe over the past few years. The patient had
a significant depression case for 2-3 weeks prior to menses
accompanied by eating compulsions. The Patient was
over-weight (203 lbs) and desired weight loss.
Attempts at dieting fail during pre-menstrual attacks of
depression. Mood drops so low as to debilitate;
she often would not leave her home, she avoided social
situations and binges. Occasionally, work time was
lost. She denied purging. She described her
pre-menstrual phase as a time when she “feels crazy” and
out-of-control of her person. She is plagued by
negative thought patterns, as well as
obsessive/compulsive thoughts and behaviors.
The patient was put
on the NeuroResearch Clinics protocol (Level I).
On follow-up, her dosage was increased to Level II, then
Level III. The patient experienced appetite
suppression during the first two weeks of menstrual
cycle (maintaining a 900 cal/day diet). Two week
prior to menses, her appetite would surge and her
depression case would return full force. Serum labs
revealed early stages of hypoestrogenism, but too early
to consider HRT.
The DBS Labs urinary
neurotransmitter lab testing was ordered.
Serotonin value was 19738; dopamine was 1280. The
patient was switched to a different 5 HTP with
tyrosine combination. She began the following dosing
schedule based on neurotransmitter testing.
One month later,
symptoms were significantly improved!
Prior to treatment
she described herself as having “one good week a month”,
she now said she felt great most days. She
described her PMDD as “slight edginess that is totally
manageable”. She also commented that she had less
interest in food, fewer obsessive/compulsive thoughts,
watched less television and improved motivation and
creative energy.
One month later, the
patient returned for a follow-up. She reported her
energy and motivation had decreased. Appetite
suppression was intact weeks 1-3 of her cycle, but
slightly reduced during her menses. Otherwise she
still feels “fantastic” and “has her self-esteem back”.
Friends and co-workers notice that she “smiles all the
time”. She has a romantic interest, for the
first time in many years.
A second urinary
neurotransmitter lab test was done. Serotonin
value was 62749; dopamine was 1465. Serotonin
remained in Phase 3, while dopamine moved from Phase 1
to Phase 3. For her 5-HTP, tyrosine, levodopa, and cysteine
dosing protocol, we raised tyrosine dosing and reduce
the levodopa dosing.
One month follow-up
(6 months from first office visit): person reports
motivation and energy have returned. There are no
PMDD symptoms. She says, she “doesn’t remember
ever feeling this good”. Her romantic interest
has evolved into a new relationship. Person weight
is 184 and she visibly glows.
Depression
Case
Its no secret, NeuroResearch Clinics uses the nutrients 5-HTP, tyrosine,
levodopa,
and cysteine to treat medical
patients in order to get these
results. Proper
use of these simple ingredients in
medical treatment is not simple.
From time to time a patient will
say, "Why do I want to take that, I
can go to a health food store and
buy it?" People off the street
buying in a health food store is
like going to an art store and
buying a bunch of oil paints then
going home and expecting to paint
like a mater artist even though
there was no previous painting
experience. These nutrients have
tremendous potential due to their
chemical properties. This potential
is only fully realized in the hands
of the trained professional using
neurotransmitter testing. Treatment
is not just giving a nutrient pill, it is the whole medical management approach doctors are trained in to insure that that treatment is on track in order to get symptoms under control.
The Peer Reviewed Research
of NeuroResearch Clinics
The neurotransmitter treatment research findings of NeuroResearch Clinics
have not been ignored. The University of
Minnesota Medical School is writing a series of
papers on the neurotransmitter testing research of NeuroResearch Clinics. The first of a series of papers by University of Minnesota Medical School based on the neurotransmitter testing research of NeuroResearch was published in "NeuroPsychiatric Disease and Treatment" May 1, 2009. Ingrid
Kohlstadt, MD of Johns Hopkins in her new
medical text book released February 7, 2009
included a chapter on depression written by
Marty L. Hinz, MD President Clinical
Research NeuroResearch Clinics outlining in
depth the proper use of amino acids and
neurotransmitter testing in treatment of
depression.
Depression
Case |
